Expert Information for Patients, GPs, and Specialist Nurses
š What Is CPA?
Chronic Pulmonary Aspergillosis (CPA) is a long-term fungal lung infection caused by Aspergillus, typically A. fumigatus. It occurs in individuals with underlying lung damage and can progress slowly over months to years. It includes several subtypes ranging from cavitary lesions to fibrosing disease and fungal balls (aspergillomas).
𧬠Subtypes of CPA
| Subtype | Description |
|---|---|
| Simple aspergilloma | Fungal ball within a pre-existing lung cavity |
| Chronic cavitary pulmonary aspergillosis (CCPA) | Multiple cavities ± fungal balls; progressive |
| Chronic fibrosing pulmonary aspergillosis | Advanced form with fibrosis and volume loss |
| Subacute invasive aspergillosis (SAIA) | Intermediate between CPA and invasive disease; more rapid progression over weeks to months |
| Aspergillus nodules | Discrete nodules without cavitation; may mimic malignancy |
š„ Who Is at Risk?
CPA typically affects people with pre-existing lung disease or immune dysfunction, including:
-
Tuberculosis (old or active)
-
COPD and emphysema
-
Bronchiectasis
-
Sarcoidosis
-
Prior pneumothorax
-
Lung cancer or surgery
-
Diabetes mellitus
-
Low-dose or chronic steroid use
ā ļø Common Symptoms
CPA symptoms often evolve insidiously over >3 months:
-
Chronic productive cough
-
Haemoptysis (may be mild or massive)
-
Fatigue and weight loss
-
Breathlessness
-
Chest discomfort
-
Fever (occasional)
š§Ŗ Diagnosis
Diagnosis of CPA requires the combination of:
-
Symptoms ā„3 months
-
Imaging:
-
CT chest: cavitary lesions, pleural thickening, aspergilloma, fibrotic changes
-
-
Microbiology:
-
Positive sputum culture, PCR, or histopathology for A. fumigatus
-
-
Serology:
-
Elevated Aspergillus IgG antibodies (essential for diagnosis)
-
-
Exclusion of other diseases:
-
Especially active TB, malignancy, and bacterial infections
-
š Treatment
First-Line:
-
Oral triazole antifungals (minimum 6 months, often longer)
-
Itraconazole
-
Voriconazole
-
Posaconazole
-
-
Therapeutic drug monitoring is crucial
Additional:
-
Inhaled antifungals (e.g. amphotericin B) in selected cases
-
Surgery for localised disease or life-threatening haemoptysis (if fit)
-
Bronchial artery embolisation for bleeding control
-
Physiotherapy and nutritional support
š§¾ Monitoring
-
CT scan every 3ā6 months during treatment
-
Aspergillus IgG titres to monitor disease activity
-
Liver function and antifungal levels (monthly at minimum)
-
Symptom tracking (cough, energy, weight, breathlessness)
š More Information
-
Referral: Hospital patients can be referred to the National Aspergillosis Centre (NAC) for diagnosis, treatment, and specialist input. NAC does not accept referrals directly from a GP – GP’s should refer to their local Infectious Disease or Respiratory service.
-
Patient Support: aspergillosis.org, NAC Facebook Group
-
Guidelines: CPA Guidelines
Share this post
Latest News posts
News archive
- ABPA
- Air Quality
- Airway Clearance, Diagnosis & Physiotherapy
- Antifungals
- Aspergilloma
- Aspergillus Bronchitis
- Biologics
- Blood Tests
- CPA
- Carers & Family
- Communities
- Complementary & Supplements
- Complications
- Conditions
- Diagnostics
- Environment
- Events & Recordings
- GP Guidance
- General interest
- Housing & Damp
- Imaging
- Immune System
- Lifestyle & Coping
- Living with Aspergillosis
- Mental Health
- Monitoring
- Monitoring & Safety
- NAC & Guidance
- NAC Announcements
- Other
- Other Forms Aspergillosis
- Patient Research
- Pets & Animals
- Professional Guidance
- Recordings
- Research
- Research Summaries
- SAFS / Severe Asthma
- Side Effects
- Steroids
- Symptoms
- Travel and Insurance
- Treatment
- Vaccines
- Weekly Updates
